ASCO: Sarclisa is first anti-CD38 to significantly improve ... - Sanofi
Jun 3, 2024 · If approved, Sarclisa would be the first anti-CD38 therapy in combination with standard-of-care VRd in newly diagnosed patients not eligible for transplant, which would be the third indication for Sarclisa in multiple myeloma.
Press Room - Sanofi US News
Aug 8, 2024 · Sarclisa (isatuximab) is a monoclonal antibody that binds to a specific epitope on the CD38 receptor on MM cells, inducing distinct antitumor activity. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activity.
Press Room - Sanofi US News
Sep 20, 2024 · The US Food and Drug Administration (FDA) has approved SARCLISA (isatuximab-irfc) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first line treatment option for adult patients with newly diagnosed multiple myeloma (NDMM) who are not eligible for autologous stem cell transplant (ASCT).
Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple …
Sarclisa is the first anti-CD38 therapy in combination with standard-of-care VRd to significantly reduce disease progression or death (by 40%) compared to VRd alone for patients with NDMM...
Sanofi targets first-line myeloma as Sarclisa delivers trial win
Dec 7, 2023 · In the currently mismatched CD38 antibody race, Sanofi’s Sarclisa has delivered a pivotal trial win, which might help the lagging follower level the playing field a little.
Sanofi's Approved Blood Cancer Drug Sarclisa Shows Improved …
Aug 8, 2024 · On Thursday, Sanofi SA (NASDAQ: SNY) reported new results from the GMMG-HD7 phase 3 study of Sarclisa in combination with lenalidomide, bortezomib, and dexamethasone (RVd) versus RVd induction ...
Press Release: Sarclisa approved in the US as the first anti-CD38 ...
Sep 20, 2024 · Sarclisa is the first anti-CD38 therapy in combination with standard-of-care VRd to significantly reduce disease progression or death (by 40%) compared to VRd alone for patients with NDMM...
FDA approves Sarclisa with bortezomib, lenalidomide, and …
On September 20, 2024, the Food and Drug Administration approved isatuximab-irfc (Sarclisa, Sanofi-Aventis U.S. LLC) with bortezomib, lenalidomide, and dexamethasone for adults with newly...
FDA Approves Sarclisa with VRd | Int'l Myeloma Foundation
Sep 20, 2024 · The IMROZ trial showed that when Sarclisa is added to Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone (VRd) in newly diagnosed multiple myeloma (NDMM) patients who are not eligible for autologous stem cell transplant (ASCT), these patients experienced longer progression-free survival (PFS) compared to those who received VRd-alone.
ASCO24: Sanofi’s Sarclisa looks to gain an edge in multiple …
Jun 4, 2024 · Sarclisa, a CD38-directed cytolytic human monoclonal antibody, was first approved as a combination treatment for adults with MM in 2021. According to GlobalData’s consensus forecasts, The therapy is anticipated to generate global sales of $887m in 2030.
- Some results have been removed